Anti-CD147 CAR mRNA-LNP
CD147 (cluster of differentiation 147) is a member of the immunoglobulin superfamily and is encoded by the BSG gene. This glycoprotein, originally known as a matrix metalloproteinase (MMP) modulator, was considered a potential target for cancer therapy. CD147 is overexpressed in cancer cells and promotes the malignant properties of cancer cells. Since CD147 is associated with certain monocarboxylate transporters, it is considered a key metabolic regulator in cancer. CD147 also regulates the angiogenic process by regulating the production of vascular endothelial growth factor (VEGF) in tumor and stromal cells. This product is designed as a tool for the delivery and expression of anti-CD147 CAR mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-CD147 CAR mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-CD147 CAR in this product is approximately 56 kD and consists of anti-CD147 scFv (single-chain variable fragment) linked to a second-generation CAR (chimeric antigen receptor) containing the CD8 hinge and transmembrane domain and 4-1BB and CD3ζ signaling domains. The full-length amino acid sequence of this anti-CD147 CAR mRNA-LNP product is available upon request.